OPK Health, Inc. OPK and Entera Bio Ltd. ENTX recently announced the positive pharmacokinetic outcomes from their joint study that combines Entera's exclusive N-Tab technology with a long-acting, ...

$OPK insiders have traded $OPK stock on the open market 9 times in the past 6 months. Of those trades, 9 have been purchases and 0 have been sales. Here’s a ...

OPKO Health, Inc. (NASDAQ:OPK) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company, in partnership with Entera Bio Ltd., announced that new data for ...

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But long term OPKO Health, Inc. (NASDAQ:OPK) shareholders have had a particularly ...

OPKO Health, Inc. OPK posted earnings per share of 3 cents for the third quarter of 2025, flat year over year. Earnings beat the Zacks Consensus Estimate of a loss of 2 cents per share by 250.00%.

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an Opko Health Inc. (NASDAQ:OPK) company, announced on October 29 a license and ...

OPK and PFE received FDA approval for Ngenla in June. This enables OPK to receive royalties going forward. OPK has continued to lose money due to its lab business. The business had sales fall off ...

The latest price target for OPKO Health (NASDAQ:OPK) was reported by JP Morgan on November 20, 2025. The analyst firm set a price target for $0.00 expecting OPK to fall to within 12 months (a possible ...

On April 19, 2023 at 10:25:48 ET an unusually large $110.00K block of Call contracts in Opko Health (OPK) was sold, with a strike price of $1.00 / share, expiring in 58 day(s) (on June 16, 2023).

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.